On March 26, Charles River Laboratories will host a premier Cell & Gene Therapy Summit, bringing together leading experts, biotech executives, innovators, and investors from across the advanced therapies ecosystem for a day of insight, collaboration, and discovery. This dynamic event will explore emerging modalities in cell and gene therapy, the real-world patient impact of these breakthroughs, and the complex journey from scientific discovery to clinical and commercial success.
The program will feature thought-provoking panels, patient perspectives, and presentations from more than 10 innovative startups from the Massachusetts biotech ecosystem, showcasing some of the most promising technologies shaping the future of medicine. Attendees will also gain valuable insights from a high-profile investor panel featuring leaders from Johnson & Johnson, MassVentures, MPM BioImpact, Polaris Partners, and others, discussing current market dynamics, investment trends, and the future of funding in this rapidly evolving field.
The day will conclude with a networking reception and scientific poster session, providing an exceptional opportunity to connect with pioneers, entrepreneurs, and investors driving the next generation of cell and gene therapies. An unmissable gathering for anyone shaping—or following—the future of advanced therapeutics.
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events, and provides this content and information as a convenience to visitors to the MLSC website.
Olaris is a precision diagnostics company that is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging their CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, they are able to harness the power of the body’s own communication system to discover and develop their pipeline of myOLARIS precision diagnostics.
